Illumina Names Abgenix CEO to Board of Directors | GenomeWeb

NEW YORK, June 4 – Illumina said Monday that R. Scott Greer, chairman and CEO of Abgenix, had been elected to its board of directors.

"We are honored that Scott has agreed to join our board. He brings a solid record of leadership and accomplishment in the life sciences industry and his insight and experience will be a tremendous asset to the company," said Jay Flatley, Illumina’s CEO, said in a statement.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: nasal microbial communities in asthma patients; sequencing-based way to detect, track schistosomiasis; and more.

The New York Times speaks with Vanderbilt's John Anthony Capra about Neanderthal genes in modern humans.

A draft guidance from the FDA suggests the agency wants to more tightly control gene-edited animals, according to Technology Review.

Researchers were among this weekend's protesters bemoaning the new US administration, Vox reports.